早期PSA密度动力学预测中危前列腺癌大分割立体定向消融放疗后的生化失败和局部失败
本研究基于219例未接受激素治疗的中危前列腺癌患者(来自5×9 Gy前列腺癌SABR的2期研究),探讨放疗后3-6个月PSA密度(PSA-D)对生化失败和局部失败的预测价值。中位随访60.3个月,7年生化无复发生存率(bRFS)在中危有利组为98.0%、中危不利组为84.5%(P=0.02)。3个月PSA-D浓度(切点0.08 ng/ml²)和3-6个月衰减斜率(切点-0.45)可预测长期bRFS。
要点
- 中位随访60.3个月,7年bRFS中危有利组98.0% vs 中危不利组84.5%(P=0.02)。
- 3个月PSA-D>0.080 ng/ml²者前列腺内局部复发11.0% vs ≤0.080 ng/ml²者1.7%(P=0.01)。
- 中危不利组中双不良PSA-D者7年bRFS 47.5% vs 其余有利动力学者94.1%(P=0.0006)。
核心结论
- 治疗后早期PSA-D动力学超越治疗前风险分层对肿瘤复发的预测,并细化中危前列腺癌表型的生物学特征。
- 双不良PSA-D算法可作为验证前列腺癌放射抵抗分类器的工具,具有治疗意义。
研究设计与样本
- 队列研究,219例未接受激素治疗、NCCN中危前列腺癌患者,来自5×9 Gy前列腺癌SABR的2期研究。
主要发现
- 中位随访60.3个月(范围46-76个月),7年bRFS中危有利组98.0% vs 中危不利组84.5%(P=0.02)。
- 14例患者出现Phoenix定义的生化PSA复发(bRFS),中位时间34.2个月,其中11例经68Ga-PSMA PET/CT确认,8例显示示踪剂摄取位于治疗前优势前列腺内病灶部位。
- 3个月PSA-D浓度(切点0.08 ng/ml²)和3-6个月衰减斜率(切点-0.45)可预测长期bRFS。
- 中危不利组中25/148例检出双不良PSA-D,7年bRFS 47.5% vs 其余123例有利PSA-D动力学者94.1%(P=0.0006)。
- 3个月PSA-D>0.080 ng/ml²者前列腺内局部复发11.0% vs ≤0.080 ng/ml²者1.7%(P=0.01);淋巴结进展分别为2.3% vs 4.3%(P=0.68)。
关键数值与推荐
- 3个月PSA-D切点0.08 ng/ml²,3-6个月衰减斜率切点-0.45,均可预测长期bRFS。
- 双不良PSA-D置换在中危不利组中检出25/148例,7年bRFS 47.5% vs 有利动力学者94.1%(P=0.0006)。
- 3个月PSA-D>0.080 ng/ml²者前列腺内局部复发11.0% vs ≤0.080 ng/ml²者1.7%(P=0.01)。
- 淋巴结进展在3个月PSA-D>0.080 ng/ml²者2.3% vs ≤0.080 ng/ml²者4.3%(P=0.68)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The present study explores PSA density (PSA-D) as predictor of biochemical and local failure in organ-confined prostate cancer at 3-6 months after hypofractionated stereotactic ablative radiotherapy (SABR). METHODS AND MATERIALS: A cohort of 219, hormone-naïve, NCCN intermediate-risk prostate cancer patients were derived from a phase 2 study of 5 × 9 Gy prostate cancer SABR. PSA-D was calculated at 3 and 6 months by dividing serum PSA by the MR-derived prostate CTV, while the slope of the 3-6 months curve was used to express the kinetics of PSA-D decay. RESULTS: The median follow-up was 60.3 (range 46-76) months, and the actuarial 7-year bRFS was 98.0% for intermediate-risk favorable (FIR) patients versus 84.5% for the unfavorable (UIR) subgroup (P = 0.02). Fourteen patients developed a Phoenix-defined biochemical PSA relapse (bRFS) at a median of 34.2 months, 11 confirmed with 68Ga-PSMA PET/CT scan that revealed tracer uptake at the site of dominant intraprostatic pretreatment lesion in 8 patients. The 3-month PSA-D concertation (cut-off 0.08 ng/ml2) and 3-6 months decay slope (cut-off -0.45) values were predictive of long-term bRFS. A dual adverse PSA-D permutation was detected in 25/148 UIR patients, exhibiting 47.5% 7-year bRFS compared with 94.1% for the remaining 123 UIR patients with favorable PSA-D kinetics (P = 0.0006). Intraprostatic local relapse in patients with a 3-month PSA-D > 0.080 ng/ml2 was 11.0% vs. 1.7% for patients with PSA-D ≤ 0.080 ng/ml2 (P = 0.01) and 2.3% vs. 4.3%, respectively, for nodal progression (P = 0.68). CONCLUSIONS: Early post-treatment PSA-D kinetics transcends pre-treatment risk stratification of tumor relapse and adds a nuance in the biological characterization of intermediate-risk prostate cancer phenotypes. The dual adverse PSA-D algorithm may serve as a tool to validate current search of classifiers of radioresistance in prostate cancer with therapeutic implications.
引用
- Greco C, Pares O, Pimentel N, et al. Early PSA density kinetics predicts biochemical and local failure following extreme hypofractionated radiotherapy in intermediate-risk prostate cancer. Radiother Oncol. 2022. PMID: 35189157. doi:10.1016/j.radonc.2022.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。